Publications by authors named "Fabrizio Pirro"
Objective: To compare the early and midterm clinical outcomes of patients undergoing two different surgical procedures (stentless biological Bentall [SBB] vs. valve-sparing David Reimplantation [VSDR]) for aortic root dilatation, with or without concomitant aortic valve pathology.
Methods: A population of 106 patients underwent aortic root replacement from 2004 to 2015 at our unit.
Background: This study evaluated the early and intermediate-term clinical and hemodynamic results after implant of the Medtronic 3F (Minneapolis, MN) stentless aortic valve.
Methods: Between March 2007 and August 2015, 226 consecutive patients affected by aortic valve disease received a 3F valve at our unit by a single surgeon. The valve in 30 patients was included in a tubular prosthesis for a Bentall procedure.
Article Synopsis
- * The Perceval sutureless prosthesis is proposed as a viable alternative for replacing malfunctioning stentless valves.
- * The report details three successful cases of using the Perceval prosthesis to replace degenerated Sorin Pericarbon Freedom valves, highlighting the procedure's safety and reproducibility.
Objective: Stentless aortic valves have shown superior hemodynamic performance and faster left ventricular mass regression compared to stented bioprostheses. Yet, controversies exist concerning the durability of stentless valves. This case-matched study compared short- and long-term clinical outcomes of stentless LivaNova-Sorin Pericarbon Freedom™ (SPF) and stented Carpentier-Edwards Perimount (CEP) aortic prostheses.
View Article and Find Full Text PDFBackground: To analyze the long-term results after Bentall operation using the stentless Shelhigh No-React (NR)-2000 bio-root prosthesis.
Material: From 2004 to 2008, 26 consecutive, nonselected patients (mean age at surgery: 67 ± 9 years) underwent a Bentall operation using a stentless Shelhigh valved conduit at our institution. Mean preoperative Logistic-EuroSCORE was 17.
Background: Aim of this study is to verify the potential advantages and benefits of bone-marrow derived autologous stem cells implantation associated to surgical left ventricular restoration (SVR), to report a new modality of cell delivery to myocardium, and to identify possible side effects of this procedure.
Methods: Between March 2007 and March 2013, 30 patients affected by ischemic dilative cardiomyopathy who received a SVR operation were enrolled in the study. The population was divided in two groups:16 patients were randomly assigned to receive stem cells therapy in addition to SVR (groupA), 14 patients received a placebo (group B).
Background: The study aim was to investigate the hemodynamic behavior over time and ease of implant and durability of the Sorin Pericarbon Freedom (SPF)® stentless pericardial aortic xenograft.
Methods: Between March 2003 and April 2010, a total of 251 consecutive, non-selected patients (mean age 70.1 years; range: 17-89 years; 17.
Article Synopsis
- The study investigated the long-term safety and effectiveness of the LivaNova-Sorin Pericarbon Freedom™ stentless aortic valves in patients who underwent aortic valve replacement (AVR) from 2003 to 2015.
- Findings showed that most patients experienced significant improvements in heart function and low mortality rates, with 95.6% of patients remaining in New York Heart Association Class I or II after an average follow-up of nearly 9 years.
- The Sorin Pericarbon Freedom valve demonstrated comparable durability to stented valves and is recommended as a reliable option for AVR, especially in patients with smaller valve annuli.
Objectives: The aim of this study is to evaluate the ease of use and the advantages of Sorin Pericarbon Freedom (SPF) stentless valve in cases of acute bacterial endocarditis and to check the intermediate-term results after the implant of SPF with respect to resistance to infection, valve deterioration and durability.
Methods: Between June 2003 and February 2015, 26 patients with active aortic valve bacterial endocarditis underwent aortic valve replacement with SPF pericardial stentless aortic prosthesis. The mean age was 57 ± 18 years; 73% of the patients were in preoperative NYHA class III and VI.